Future Battery Minerals looks to flex in 2025
Cashed up and ready to roll further into a gold-hued 2025, Future Battery Minerals has put itself in a good position to pursue organic and inorganic growth.
Stockhead
Long Shortz: Arizona Lithium
Arizona Lithium’s Paul Lloyd breaks down the company’s updated phased development plan for the Prairie lithium project and its path to production.
Health Kick Podcast: Aroa Biosurgery
Stockhead’s health and biotech expert Tim Boreham sits down with Aroa Biosurgery CEO Brian Ward to discuss the company’s first positive cash flow quarter, despite its lowered revenue guidance.
Long Shortz: Greenvale Energy
Greenvale Energy’s Neil Biddle unpacks the company’s recent strategic shift into uranium and its growing portfolio of high-grade assets.
More Stories
It’s not just gold, these stocks have legs too
Record prices have gold in favour, but Precision Funds Management’s Dermot Woods joins Stockhead to get creative with other value ASX stocks.
Chile’s copper forecasts lift optimism
Chile’s copper commission Cochilco forecast prices of US$4.25/lb for the red metal for the next two years as demand rises.
MM8 steps closer to Ravensthorpe development
Medallion Metals is closer to securing EPBC approval, the key outstanding required to develop its 1.6Moz Ravensthorpe gold project.
Vital Signs: Wellnex Life
Nadine McGrath chats to Zack Bozinovski from Wellnex Life to learn more about the company’s health and wellness offerings.
Gold, iron ore lift in January
Gold hit a new record high and iron ore weathered a Trumpian storm, but lithium, coal and uranium battled in January.
ADX’s Italian licence has big gas potential
ADX Energy’s new Italian licence benefits from a pro-development government and the potential to host rich gas resources on Europe’s doorstep.
Gold shines as ASX nears record
The ASX has closed up over 1.2%, News Corp’s killing it, and Nissan is ditching Honda for a US electric car buddy.
Percheron closes the chapter on trial disaster
Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December’s Duchenne muscular dystrophy trial flop.
Wellnex sees growth in London adventure
Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London’s AIM exchange.
Buyers choice greets ASX on Monday
The local market has lifted strongly on Monday morning
Original URL: https://www.themercury.com.au/business/stockhead/page/3